Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) will present AI-driven polio vaccine design concepts and CMV program data at the World Vaccine Congress in Washington D.C., March 31–April 2, 2026. The company, in collaboration with the Gates Foundation, described hybrid capsid and de novo B-cell antigen approaches and will present EVX-V1 CMV antigen data on April 2, 2026.
Presentations aim to showcase AI-Immunology™ platform capabilities and early results supporting further development and potential collaborations.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Among close biotech peers, scanner activity shows only PULM moving, down about 4.4%, with no accompanying news. Other peers show mixed moves, suggesting EVAX’s action around this AI-vaccine update is more stock-specific than sector-driven.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Platform expansion | Positive | -1.5% | Expanded AI-Immunology™ into autoimmune diseases while maintaining cash runway guidance. |
| Nov 03 | New cancer candidate | Positive | +0.3% | Announced AI-designed EVX-04 AML vaccine with preclinical data showing strong T-cell responses. |
| Oct 08 | Design module launch | Positive | +10.0% | Launched automated vaccine design module integrating target discovery and design end-to-end. |
| Jul 01 | Management changes | Negative | +1.2% | CEO stepped down; CSO became interim CEO amid efforts to optimize AI-Immunology™ value. |
| Dec 12 | PoC cancer vaccine | Positive | -8.5% | Reported preclinical proof-of-concept for AI-derived precision cancer vaccine concept. |
AI-Immunology™ news has produced mixed reactions: 3 of 5 past AI-tagged releases saw price moves that diverged from their generally positive strategic tone.
Over the past 15 months, Evaxion has repeatedly highlighted advances from its AI-Immunology™ platform across cancer, infectious disease and autoimmune settings. AI-tagged updates included platform expansion into autoimmune diseases, a new precision cancer vaccine candidate EVX-04, and an automated vaccine design module, plus management changes framed around optimizing the AI platform. Today’s AI-based polio and CMV vaccine design concepts fit this pattern of leveraging AI-Immunology™ for new vaccine modalities and indications.
Historical Comparison
In the past 5 AI-tagged updates, EVAX saw an average move of about 0.31% with mixed direction. The current AI-based polio and CMV vaccine design news continues the theme of showcasing AI-Immunology™ in new indications rather than changing near-term financial guidance.
AI-Immunology™ communications have progressed from platform proof-of-concept and precision cancer vaccines to automated design tools, autoimmune expansion, and now AI-designed polio and CMV vaccine concepts.
Market Pulse Summary
This announcement showcases Evaxion’s use of its AI-Immunology™ platform to design novel polio vaccine concepts and advance the EVX‑V1 CMV program, both featured at the World Vaccine Congress. In the past, AI-tagged updates have highlighted platform expansion, new candidates and automation tools. Investors monitoring this story may focus on future data readouts, partnering activity around these concepts, and how AI-designed vaccines transition from conference-stage concepts into formal clinical development.
Key Terms
ai-immunology™ technical
capsid medical
b-cell antigen medical
cytomegalovirus medical
antigens medical
AI-generated analysis. Not financial advice.
- Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently used
- The AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen approaches
- Despite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health risk
- Evaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine Congress
COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior concepts for design of vaccines to combat polio. These concepts, and the underlying research, will be presented at the World Vaccine Congress taking place in Washington D.C. from March 31 to April 2, 2026.
Current polio vaccines are based on inactivated or attenuated versions of the virus. While these vaccines are effective, they each have shortcomings in certain settings. Thus, it has been a long-standing - but so far unreachable - goal to create a novel polio vaccine that combines the strongest aspects of the existing vaccines.
To achieve this, Evaxion has deployed AI-Immunology™ to develop novel vaccine design concepts for a next-generation polio vaccine, which may enhance the chances of completing and sustaining polio eradication once and for all.
“These new polio vaccine design concepts are great examples of how AI-Immunology™ enables novel approaches to diseases for which adequate treatment options do not exist despite decades of research. We are excited to have applied the platform within a new viral disease, further validating its capability and scalability. Initial results support further development of the new concepts, representing another potential collaboration opportunity for us,” says Birgitte Rønø, CSO of Evaxion.
Evaxion will also present data from its EVX-V1 program at the World Vaccine Congress. EVX-V1 targets Cytomegalovirus (CMV). AI-Immunology™ has discovered novel CMV antigens and EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. This broader multi-targeted strategy is expected to strengthen the protective potential of the future vaccine.
Presentations details:
Presentation title: Designing a novel poliovirus vaccine using AI-Immunology™
Session: Emerging & re-emerging diseases
Location: Room 202A
Date/Time: April 1, 2026, at 16:40 ET
Presenter: Thomas Trolle, PhD, Director, Bioinformatics at Evaxion
Abstract title: AI-powered target discovery for a novel CMV vaccine
Session: Emerging & re-emerging Diseases
Location: Room 202A
Date/Time: April 2, 2026, at 10:25 ET
Presenter: Pär Comstedt, VP, Infectious disease vaccine development at Evaxion
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
What will Evaxion (EVAX) present about polio vaccine design at the World Vaccine Congress on April 1, 2026?
When and where will Evaxion present EVX-V1 CMV data at the World Vaccine Congress 2026?
How does Evaxion describe the role of its AI-Immunology™ platform in the EVAX presentations?
Who will present Evaxion research at the World Vaccine Congress and what are their roles?
Does Evaxion state any immediate clinical or regulatory outcomes from the World Vaccine Congress presentations?
